Search our team at AdventHealth Research Institute
-
NCT06356311
MK2870-015: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaTo compare MK-2870 to TPC
with respect to OS.To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR. To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed... -
NCT06132958
MK2870-005/ENGOT-en23/GOG3095 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this trial is to: Test the safety of the trial drug, MK-2780: see how well the trial drug works, see how your body handles the trial drug. See how well MK-2870 works compared to the 2...
-
ENABLE: Clinical validation of islet autoantibody measurement in self-collected dried blood spot specimens
This study is currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: Clinical validation of islet autoantibody measurement in self-collected dried blood spot specimens.
To be enrolled in this study, you must meet certain requirements. You may be...
-
NCT06188559
BB-1701-G000-205 An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...
-
TRIPLE G: A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 versus Placebo on Calorie Intake and Energy Expenditure in Participants with Obesity Under Calorie Restriction
This study is currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purposes of this study are to look at the effect of the study drug compared to placebo (a drug that looks like the study drug but has no active medicine) on calorie intake...
-
NCT06129240
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension
This study is currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Orlando, FloridaThis is a medical research study to test an investigational form of a drug called treprostinil. “Investigational” means that the way in which treprostinil is prepared and given to patients has not...
-
NCT06041594
Treating Pulmonary Embolism with Laguna Thrombectomy System (TRUST)
This study is currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Tampa, FloridaThe purpose of this research study is to show whether an investigational device, called the Laguna™ Thrombectomy System, is safe and effective for the treatment of pulmonary embolism. The Laguna™...
-
NCT06282575
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis is an open-label, randomized, multicenter, phase 3 study to investigate the efficacy and safety of zanidatamab plus CisGem with or without a PD-1/L1 inhibitor (physician’s choice of either...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Celebration, FloridaThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary... -
NCT04408625
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
This study is currently enrolling.Associated Conditions: AlzheimersResearch Area: Neuroscience ResearchResearch Location: Orlando, FloridaThe purpose of this open label study is to assess the safety, tolerability, and effects of LY3884963 on plasma (the liquid component of blood) and/or cerebrospinal fluid (CSF; fluid from the area...
-
NCT04127578
Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL)
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaParkinson’s disease is a slowly progressive and disabling disease of the central nervous system that causes problems with movement, such as shaking, stiffness, slow movement, and difficulty walking...